Celularity (CELU) News Today $2.94 +0.02 (+0.68%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Celularity’s Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia PacificNovember 20 at 11:22 AM | markets.businessinsider.comCelularity's Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia PacificNovember 20 at 8:30 AM | globenewswire.comCelularity Inc. (NASDAQ:CELU) Sees Large Increase in Short InterestNovember 19 at 1:29 AM | americanbankingnews.comCelularity Inc. Announces Resolution of Nasdaq Listing Compliance MatterNovember 18 at 8:30 AM | globenewswire.comCelularity Inc. (NASDAQ:CELU) Sees Significant Increase in Short InterestCelularity Inc. (NASDAQ:CELU - Get Free Report) was the recipient of a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 743,700 shares, an increase of 9.3% from the October 15th total of 680,500 shares. Based on an average daily volume of 876,800 shares, the short-interest ratio is currently 0.8 days. Approximately 6.9% of the shares of the company are short sold.November 17, 2024 | marketbeat.comCelularity (NASDAQ:CELU) Stock Quotes, Forecast and News SummaryNovember 8, 2024 | benzinga.comCelularity raises FY24 revenue view to $54M-$60M from $50M-$56MNovember 7, 2024 | markets.businessinsider.comCelularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 MillionNovember 7, 2024 | finance.yahoo.comCelularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings PanelOctober 23, 2024 | globenewswire.comCelularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an AppealOctober 18, 2024 | globenewswire.comCelularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.October 16, 2024 | globenewswire.comCelularity anuncia la salida de un ejecutivoSeptember 15, 2024 | es.investing.comCelularity (NASDAQ:CELU) Shares Down 3.6% Celularity (NASDAQ:CELU) Trading Down 3.6%September 11, 2024 | marketbeat.comCelularity to Present at H.C. Wainwright’s 26th Annual Global Investment ConferenceSeptember 5, 2024 | markets.businessinsider.comCelularity to Present at H.C. Wainwright's 26th Annual Global Investment ConferenceSeptember 5, 2024 | globenewswire.comUnlocking the Secrets of Immortality: KCSA Podcast Labs Dives into $43 Billion Longevity IndustrySeptember 4, 2024 | markets.businessinsider.comCelularity Appoints Richard J. Berman to its Board of DirectorsAugust 28, 2024 | globenewswire.comCelularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q FilingAugust 23, 2024 | globenewswire.comVanguard Group Inc. Sells 3,348,288 Shares of Celularity Inc. (NASDAQ:CELU)Vanguard Group Inc. lowered its stake in Celularity Inc. (NASDAQ:CELU - Free Report) by 89.7% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 384,918 shares of the company's stock after selling 3,348,288 shares during thAugust 20, 2024 | marketbeat.comCelularity (CELU)August 11, 2024 | es.investing.comCelularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023July 31, 2024 | globenewswire.comAmniotic Products Market Size to Hit US$ 1.67 Billion By 2032, Due to Rise in Patient Population & Surgical Interventions | Research by SNS InsiderJuly 19, 2024 | finance.yahoo.comCelularity (NASDAQ:CELU) Trading 0.7% Higher Celularity (NASDAQ:CELU) Stock Price Up 0.7%June 25, 2024 | marketbeat.comCelularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual MeetingJune 3, 2024 | globenewswire.comShort Interest in Celularity Inc. (NASDAQ:CELU) Rises By 5.4%Celularity Inc. (NASDAQ:CELU - Get Free Report) was the recipient of a significant growth in short interest in the month of May. As of May 15th, there was short interest totalling 627,100 shares, a growth of 5.4% from the April 30th total of 595,000 shares. Currently, 5.9% of the shares of the company are short sold. Based on an average trading volume of 70,000 shares, the days-to-cover ratio is currently 9.0 days.June 2, 2024 | marketbeat.comCelularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q FilingMay 24, 2024 | globenewswire.comCelularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T TherapyMay 14, 2024 | globenewswire.comShort Interest in Celularity Inc. (NASDAQ:CELU) Grows By 51.4%Celularity Inc. (NASDAQ:CELU - Get Free Report) saw a large increase in short interest in April. As of April 30th, there was short interest totalling 595,000 shares, an increase of 51.4% from the April 15th total of 393,100 shares. Approximately 5.6% of the shares of the stock are sold short. Based on an average daily volume of 72,300 shares, the days-to-cover ratio is currently 8.2 days.May 12, 2024 | marketbeat.comCelularity Inc. to Host Investor and Analyst Research & Development DayApril 22, 2024 | globenewswire.comCelularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K FilingApril 19, 2024 | globenewswire.comCelularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024April 18, 2024 | globenewswire.comCelularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial ProductsApril 15, 2024 | globenewswire.comCelularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental CellsApril 8, 2024 | globenewswire.comCelularity Inc. (NASDAQ:CELU) Short Interest Down 16.8% in MarchCelularity Inc. (NASDAQ:CELU - Get Free Report) was the recipient of a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 388,300 shares, a decrease of 16.8% from the February 29th total of 466,600 shares. Based on an average trading volume of 269,900 shares, the short-interest ratio is currently 1.4 days. Approximately 3.7% of the shares of the stock are sold short.March 30, 2024 | marketbeat.comCelularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3LMarch 26, 2024 | finance.yahoo.comCelularity Inc.: Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular DystrophyMarch 20, 2024 | finanznachrichten.deCelularity Announces Submission Of Request For Orphan Drug Designation For PDA-002March 20, 2024 | markets.businessinsider.comCelularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular DystrophyMarch 20, 2024 | globenewswire.comCELU Apr 2024 10.000 callMarch 16, 2024 | finance.yahoo.comCELU Mar 2024 7.500 putMarch 15, 2024 | finance.yahoo.comCelularity CEO to Present on Cell Therapy’s Potential to Improve Longevity at 2024 ABUNDANCE SummitMarch 14, 2024 | finance.yahoo.comCelularity CEO to Present on Cell Therapy's Potential to Improve Longevity at 2024 ABUNDANCE SummitMarch 14, 2024 | globenewswire.comCelularity Inc. (NASDAQ:CELU) Short Interest Down 87.6% in FebruaryCelularity Inc. (NASDAQ:CELU - Get Free Report) was the recipient of a significant drop in short interest in February. As of February 29th, there was short interest totalling 466,600 shares, a drop of 87.6% from the February 14th total of 3,750,000 shares. Currently, 4.5% of the shares of the stock are sold short. Based on an average daily trading volume, of 264,800 shares, the short-interest ratio is currently 1.8 days.March 12, 2024 | marketbeat.comCelularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World CongressMarch 12, 2024 | globenewswire.comCelularity Inc. Class AMarch 8, 2024 | edition.cnn.comCelularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental CellsMarch 7, 2024 | globenewswire.comTrading was temporarily halted for "CELU" at 07:02 PM with a stated reason of "News pending."February 29, 2024 | marketbeat.comCelularity, Inc.: Celularity Announces 1-for-10 Reverse Stock SplitFebruary 24, 2024 | finanznachrichten.deStocks to Watch: Intuitive Machines, CelularityFebruary 23, 2024 | marketwatch.comCelularity Announce 1-for-10 Reverse Stock SplitFebruary 23, 2024 | markets.businessinsider.com Get Celularity News Delivered to You Automatically Sign up to receive the latest news and ratings for CELU and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump won. Buy this coin now. (Ad)Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher. This could be his favorite coin. CELU Media Mentions By Week CELU Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CELU News Sentiment▼0.770.45▲Average Medical News Sentiment CELU News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CELU Articles This Week▼51▲CELU Articles Average Week Get Celularity News Delivered to You Automatically Sign up to receive the latest news and ratings for CELU and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MVST News Today ATYR News Today FATE News Today BNTC News Today PYXS News Today ACB News Today TRVI News Today BMEA News Today TCRX News Today STRO News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CELU) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celularity Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celularity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
